You can buy or sell EBS and other stocks, options, ETFs, and crypto commission-free!
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. Read More Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
52 Week High
52 Week Low
Health And Wellness
Seeking AlphaMay 20
Emergent Bio's typhoid vaccine OK'd in five new EU states
Emergent BioSolutions (NYSE:EBS) announces that Vivotif (Typhoid Vaccine Live Oral Ty21a) is now approved for sale in France, Portugal, Poland, Czech Republic and Slovakia.
Yahoo FinanceMay 20
Emergent BioSolutions to Participate in Series of Investor Conferences
GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the second quarter of 2019: RBC Capital Markets – 2019 Global Healthcare Conference New York, NY May 21-22, 2019 Goldman Sachs – 40th Annual Global Healthcare Conference (1x1 Meetings Only) Rancho Palos Verdes, CA June 11-13, 2019 Scroll to continue with content Ad Three Part Advisors...
Seeking AlphaMay 15
Emergent Bio readies anthrax vaccine shipments into U.S. stockpile
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has notified Emergent BioSolutions (NYSE:EBS) that it will begin procuring its AV7909 anthrax vaccine for delivery into the Strategic National Stockpile.
Expected Aug 1, After Hours